Aktis Oncology, Inc. (AKTS)

Aktis Oncology Statistics

Total Valuation

Aktis Oncology has a market cap or net worth of $1.18 billion. The enterprise value is $942.14 million.

Market Cap	1.18B
Enterprise Value	942.14M

Important Dates

The last earnings date was Thursday, November 14, 2024, before market open.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

Aktis Oncology has 52.52 million shares outstanding. The number of shares has increased by 53.35% in one year.

Current Share Class	50.65M
Shares Outstanding	52.52M
Shares Change (YoY)	+53.35%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.44%
Owned by Institutions (%)	4.63%
Float	23.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.20
Forward PS	n/a
PB Ratio	5.85
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	169.45
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.27, with a Debt / Equity ratio of 0.06.

Current Ratio	9.27
Quick Ratio	9.18
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -26.50% and return on invested capital (ROIC) is -18.92%.

Return on Equity (ROE)	-26.50%
Return on Assets (ROA)	-14.80%
Return on Invested Capital (ROIC)	-18.92%
Return on Capital Employed (ROCE)	-28.93%
Revenue Per Employee	$73,158
Profits Per Employee	-$798,013
Employee Count	76
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	706,095

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Aktis Oncology had revenue of $5.56 million and -$60.65 million in losses. Loss per share was -$76.44.

Revenue	5.56M
Gross Profit	-58.00M
Operating Income	-72.94M
Pretax Income	-60.65M
Net Income	-60.65M
EBITDA	-70.87M
EBIT	-72.94M
Loss Per Share	-$76.44

Balance Sheet

The company has $246.22 million in cash and $11.87 million in debt, with a net cash position of $234.36 million or $4.46 per share.

Cash & Cash Equivalents	246.22M
Total Debt	11.87M
Net Cash	234.36M
Net Cash Per Share	$4.46
Equity (Book Value)	201.02M
Book Value Per Share	-162.43
Working Capital	222.51M

Cash Flow

In the last 12 months, operating cash flow was -$61.69 million and capital expenditures -$7.66 million, giving a free cash flow of -$69.34 million.

Operating Cash Flow	-61.69M
Capital Expenditures	-7.66M
Free Cash Flow	-69.34M
FCF Per Share	-$1.32

Margins

Gross Margin	n/a
Operating Margin	-1,311.94%
Pretax Margin	-1,090.81%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Aktis Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-53.35%
Shareholder Yield	-53.35%
Earnings Yield	-5.16%
FCF Yield	-5.89%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Aktis Oncology has an Altman Z-Score of -0.6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.6
Piotroski F-Score	n/a